The federal marijuana rescheduling process was already moving slower than a guy trying to roll a joint in oven mitts. Now it’s getting hit with another legal challenge — this time from MMJ International Holdings, a pharmaceutical cannabis company claiming the whole thing may be unconstitutional from the ground up.
MMJ officially jumped into the DEA’s upcoming June 29 rescheduling hearing with a laundry list of complaints aimed squarely at the federal government. Their argument basically boils down to this: “We followed every federal rule you told us to follow… so why are we still getting buried while the rest of the industry runs wild?”
And honestly? It’s not a completely crazy question.
According to MMJ, they spent eight years grinding through the federal pharmaceutical maze — FDA Investigational New Drug applications, orphan drug designations, DEA inspections, compliance paperwork, the whole bureaucratic nightmare package. Meanwhile, thousands of state cannabis businesses just started selling products under state law while federal agencies looked the other way.
Now MMJ is arguing that the DEA’s hearing system itself may not even be legal anymore.
That’s where this thing gets spicy.
The Department of Justice reportedly admitted in federal court that the DEA’s Administrative Law Judge system has constitutional problems involving presidential oversight and separation of powers. MMJ says if the system running the hearing is unconstitutional, then the entire rescheduling process could be vulnerable to court challenges before it even begins.
So while politicians and cannabis investors keep yelling “Schedule III is coming!” there’s now a very real possibility the process could get tangled in federal lawsuits, procedural fights, and enough legal paperwork to kill a small forest.
To make things even messier, multiple states are already challenging the federal government’s cannabis moves in court, arguing the DEA rushed parts of the Schedule III process without proper procedure.
The federal government did already move certain FDA-approved marijuana products and state medical marijuana programs into Schedule III territory earlier this year, while broader cannabis rescheduling is still being debated.
Translation: we now have a half-in, half-out federal cannabis system that somehow became even more confusing than before.
Classic America.
At this point, the marijuana rescheduling process feels less like a historic policy reform and more like a season finale where every character files a lawsuit before the credits roll.
Dabbin-Dad Newsroom
